B
MYGN icon

Baird’s Myriad Genetics MYGN Stock Holding History

Baird’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		$2.96M Buy
83,752
+8,075
+11% +$289K 0.03% 458
2014
Q4 		$2.58M Buy
75,677
+598
+0.8% +$21.2K 0.03% 485
2014
Q3 		$2.9M Buy
75,079
+2,253
+3% +$84.1K 0.04% 369
2014
Q2 		$2.83M Buy
72,826
+10,857
+18% +$404K 0.04% 392
2014
Q1 		$2.12M Buy
61,969
+17,131
+38% +$531K 0.03% 458
2013
Q4 		$941K Buy
44,838
+27,543
+159% +$697K 0.02% 631
2013
Q3 		$406K Buy
17,295
+237
+1% +$6.73K 0.01% 861
2013
Q2 		$458K Buy
+17,058
New +$494K 0.01% 796

Other funds holding MYGN

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BTS
BB&T Securities Richmond, Virginia $10.9B AUM 5.31% 1-Year Est. Return
SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
IAM
Iridian Asset Management Westport, Connecticut $247M AUM 20.65% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Baird's MYGN Position: Q1 2015 in Review

Baird increased its Myriad Genetics (MYGN) stake by 11% in Q1 2015, buying an estimated $289K and bringing the position to 83,752 shares worth $2.96M. The position accounts for 0.03% of the portfolio, ranked #458.

Baird first reported a position in MYGN in Q2 2013 and has held it in 8 quarters since. 251 funds tracked by Wall St. Rank hold MYGN as of Q1 2015.

  • Baird held 83,752 shares of Myriad Genetics worth $2.96M as of Q1 2015.
  • Baird bought 8,075 Myriad Genetics shares in Q1 2015, an estimated $289K.
  • Myriad Genetics made up 0.03% of Baird's portfolio in Q1 2015, its #458 holding.
  • Baird first reported a position in Myriad Genetics in Q2 2013 and has held it in 8 quarters since.
  • 251 funds tracked by Wall St. Rank held Myriad Genetics as of Q1 2015.

Based on Baird's 13F filing for Q1 2015, filed 13 May 2015.